Touyun Biotech Group Reports Turnaround in Interim Results
Touyun Biotech Group Limited reported a significant turnaround in its interim results for the six months ending June 30, 2025, achieving a profit of HK$28.05 million, compared to a loss of HK$48.82 million in the same period of 2024. This improvement was attributed to gains in other income and reduced losses from discontinued operations. The company, listed on the Hong Kong Stock Exchange under stock code 1332, operates in the biotechnology sector, focusing on treasury investment and money lending.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from China Touyun Tech Group ( (HK:1332) ) is now available.
Touyun Biotech Group Limited reported its unaudited interim results for the six months ending June 30, 2025, showing a significant turnaround with a profit of HK$28.05 million compared to a loss of HK$48.82 million in the same period in 2024. This improvement was driven by gains in other income and a reduction in losses from discontinued operations, positioning the company more favorably in its market.
More about China Touyun Tech Group
Touyun Biotech Group Limited operates in the biotechnology industry, focusing on treasury investment, money lending, and the sale of goods and services. The company is incorporated in Bermuda and is listed on the Hong Kong Stock Exchange under the stock code 1332.
Average Trading Volume: 207,396
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$227.3M
For an in-depth examination of 1332 stock, go to TipRanks’ Overview page.
Trending Articles:
- A “Back Door Data Center Play”: Target Hospitality Stock (NASDAQ:TH) Surges With Stifel Call
- ‘Hundreds of Lawsuits’ Coming Soon Against Roblox Over Child Abuse
- 3 Penny Stocks to Watch Now, 8/19/25
Disclaimer & DisclosureReport an Issue
